evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,155 questions · 1,191 findings · 195 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 209 · 17.5%GRADE not reported 51 · 4.3%Very low 256 · 21.5%Low 273 · 22.9%Moderate 284 · 23.8%High 118 · 9.9%

Summary of findings: Low‐moderate GI diet vs moderate‐high GI diet (maternal outcomes)

Hypertensive disorders of pregnancy: severe hypertension or pre‐eclampsia · pregnant women with GDM

It is very uncertain whether summary of findings: Low‐moderate GI diet changes hypertensive disorders of pregnancy: severe hypertension or… compared with moderate‐high GI diet (maternal outcomes) (very low certainty).

1 finding from 1 review

Summary of findings: Low‐moderate GI diet vs moderate‐high GI diet (maternal outcomes)

Eclampsia · pregnant women with GDM

It is very uncertain whether summary of findings: Low‐moderate GI diet changes hypertensive disorders of pregnancy: eclampsia compared with moderate‐high GI diet (maternal outcomes) (very low certainty).

1 finding from 1 review

Summary of findings: Low‐moderate GI diet vs moderate‐high GI diet (neonatal/child/adulthood outcomes)

Large‐for‐gestational age · pregnant women with GDM

Summary of findings: Low‐moderate GI diet showed no clear difference in large‐for‐gestational age compared with moderate‐high GI diet (neonatal/child/adulthood outcomes) (low certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema

It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Low vs moderate‐high nasal continuous positive airway pressure levels

Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · health problem or population

The review found no eligible studies for this question.

2 findings from 1 review